Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Drugs and Therapy
Erschienen in: Cardiovascular Drugs and Therapy 1/2008

01.02.2008

CREB Activation and Ischaemic Preconditioning

verfasst von: E. Marais, S. Genade, A. Lochner

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Previous studies from our laboratory showed that activation of p38 MAPK is one of the triggers of ischaemic preconditioning. The signalling events downstream of p38 MAPK and their links to the putative final effectors of preconditioning are not clear. The cAMP responsive element-binding protein (CREB) is also phosphorylated by exposure to short episodes of ischaemia/reperfusion, suggesting a triggering action. The aim of this study was to systematically investigate (1) the signalling pathways leading to CREB phosphorylation during an ischaemic or β-adrenergic preconditioning protocol (2) changes in CREB phosphorylation during sustained ischaemia and their significance in ischaemia/reperfusion injury.

Methods

The isolated perfused working rat heart was preconditioned by 1 × 5 min global ischaemia or 3 × 5 min global ischaemia and freeze-clamped. Drugs to manipulate CREB activation were added 5 min before onset of ischaemia. Non-preconditioned and preconditioned hearts were subjected to 25 min global or 35 min regional ischaemia, followed by 30 min reperfusion. Infarct sizes were determined using tetrazolium staining. Phosphorylation of CREB was determined by Western blots.

Results

Exposure of hearts to 5 min global ischaemia followed by reperfusion, significantly increased CREB phosphorylation This is mediated by, amongst others, release of endogenous catecholamines and adenosine, as indicated by the use of receptor blockers. Events downstream of receptor stimulation were evaluated using inhibitors for PKA (H89), MSK-1 (H89, Ro318220), PKC (bisindolylmaleimide), p38 MAPK (SB203580) and ERK (PD98059). Activation of PKA, PKC, ERK and p38 MAPK is involved in preconditioning-induced CREB phosphorylation. Ischaemia-induced activation of iPLA2 and cPLA2 also contribute to CREB phosphorylation as indicated by the use of the inhibitors 4-bromo-enol-lactone (BEL) and AACOF3, respectively. Inhibition of CREB phosphorylation by either BEL or AACOF3 during a preconditioning protocol partially attenuated cardioprotection. CREB phosphorylation was attenuated during sustained global ischaemia of both non-preconditioned and preconditioned hearts.

Conclusions

These data suggest that CREB phosphorylation during an ischaemic preconditioning protocol may contribute to triggering preconditioning, while reduced phosphorylation during sustained ischaemia does not appear to be associated with cardioprotection.
Literatur
1.
Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124–36.PubMed
2.
Shaywitz A, Greenberg M. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Ann Rev Biochem 1999;68:821–61.PubMedCrossRef
3.
Wiggin G, Soalaga A, Foster J, Murray-Tait V, Cohen P, Arthur J. MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF-1 in fibroblasts. Mol Cell Biol 2002;22:2871–81.PubMedCrossRef
4.
Ginty P, Bonni A, Greenberg M. Nerve growth factor activates a Ras-dependent protein kinase that stimulates c-fos transcription via phosphorylation of CREB. Cell 1994;77:713–25.PubMedCrossRef
5.
Snowden A, Perkins N. Cell cycle regulation of the transcriptional coactivators p300 and CREB-binding protein. Biochem Pharmacol 1998;55:1947–54.PubMedCrossRef
6.
Deak M, Clifton A, Lucocq, Alessi D. Mitogen- and stress-activated protein kinase 1 (MSK1) is directly activated by MAPK and SAKP2/p38 and may mediate activation of CREB. EMBO J 1998;17:4426–41.PubMedCrossRef
7.
Lee J, Laydon P, McDonnell P, Gallagher T, Kumar S, Green D. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739–46.PubMedCrossRef
8.
Xing J, Ginty D, Greenberg M. Coupling of the Ras-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 1996;273:959–69.PubMedCrossRef
9.
Zanassi P, Paolillo M, Feliciello A, Avvedimento EV, Gallo V, Schinelli S. cAMP-dependent protein kinase induces cAMP-response-element-binding protein phosphorylation via an intracellular calcium release /ERK dependent pathway in striatal neurons. J Biol Chem 2001;276:11487–95.PubMedCrossRef
10.
Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Keusch JE. Akt/protein kinase B upregulates Bcl-2 expression through cAMP response-element binding protein. J Biol Chem 2000;275:10761–66.PubMedCrossRef
11.
Siu Y-T, Jin D-Y. CREB—a real culprit in oncogenesis. FASEB J 2007;274:3224–32.
12.
Jaworski J, Mioduszewska B, Sanchez-Capelo A, Figel I, Habas A, Gozdz A, Proszynski T, Hefman M, Mallet J, Kaczmarek L. Inducible cAMP early repressor, an endogenous antagonist of cAMP responsive element-binding protein, evokes neuronal apoptosis in vitro. J Neurosci 2003;23:4519–23.PubMed
13.
El Jamali A, Freund C, Rechner C, Scheidereit C, Dietz R, Bergmann MW. Reoxygenation after severe hypoxia induced cardiomyocyte hypertrophy in vitro: activation of CREB downstream of GSK-3beta. FASEB J 2004;18:1096–98.PubMed
14.
Marais E, Genade S, Huisamen B, Strijdom JG, Moolman JA, Lochner A. Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion. J Mol Cell Cardiol 2001;33:769–78.PubMedCrossRef
15.
Marais E, Genade S, Salie R, Huisamen B, Maritz S, Moolman JA, Lochner A. The temporal relationship between p38 MAPK and HSP27 activation in ischaemic and pharmacological preconditioning. Bas Res Cardiol 2005;100:35–47.CrossRef
16.
Sato M, Cordis GA, Maulik N, Das DK. SAPKs regulation of ischemic preconditioning. Am J Physiol 2000;279:H901–7.
17.
Williams SD, Ford DA. Calcium-independent phospholipase A2 mediates CREB phosphorylation and c-fos expression during ischemia. Am J Physiol 2001;281:H168–76.
18.
Edoute Y, Van der Merwe E, Sanan D, Kotze JCN, Steinmann C, Lochner A. Normothermic ischaemic arrest of the isolated working heart. Effect of time and reperfusion on myocardial ultrastructure, mitochondrial oxidative function and mechanical recovery. Circ Res 1998;58:663–78.
19.
Moolman JA, Genade S, Malan JF, Williams K, Salie R, Jordaan A, Lochner A. Preconditioning with global ischaemia in the isolated working rat heart model. Cardiovasc Drugs Therap 1995;9:103–15.CrossRef
20.
Lochner A, Genade S, Moolman JA. Ischemic preconditioning: infarct size is a more reliable endpoint than functional recovery. Bas Res Cardiol 2003;98:337–46.CrossRef
21.
Schömig A, Haas M, Richardt G. Catecholamine release and arrhythmias in acute myocardial ischaemia. Eur Heart J 1991;12:38–47.PubMed
22.
Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003;83:1113–51.PubMed
23.
Markou T, Hadzopoulou-Cladaras M, Lazou A. Phenylephrine induces activation of CREB in adult rat cardiac myocytes through MSK1 and PKA signaling pathways. J Mol Cell Cardiol 2004;37:1001–11.PubMedCrossRef
24.
Maldonado C, Cea P, Adasme T, Collao A, Diaz-Araya G, Chiong M, Lavandero S. IGF-1 protects cardiac myocytes from hyperosmotic stress-induced apoptosis via CREB. Biochem Biophys Res Comm 2005;336:1112–8.PubMedCrossRef
25.
Brand T, Sharma HS, Fleischmann KE, Duncker DJ, McFalls EO, Verdouw PD, Schaper W. Proto-oncogene expression in porcine myocardium exposed to ischemia and reperfusion. Circ Res 1992;71:1351–60.PubMed
26.
Mubagwa K, Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc Res 2001;52:25–39.PubMedCrossRef
27.
Germach R, Dickenson JM. Adenosine triggers preconditioning through MEK/ERK1/2 signaling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. J Mol Cell Cardiol 2005;39:429–42.CrossRef
28.
Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc Drug Rev 2006;24:261–74.PubMedCrossRef
29.
Nagy N, Shiroto K, Malik G, Huang C-K, Gaestel M, Abdellatif M, Tosaki A, Maulik N, Das DK. Ischemic preconditioning involves dual cardioprotective axes with p38 MAPK as upstream target. J Mol Cell Cardiol 2007;42:981–90.PubMedCrossRef
30.
Davis PD, Hill CH, Keech E, Lawton G, Nixon JS, Sedgwick A et al. Potent selective inhibitors of protein kinase C. FEBS Lett 1989;259:61–3.PubMedCrossRef
31.
Alessi DR. The protein kinase C inhibitors Ro31822 and GF 109203x are equally potent inhibitors of MAPKAP kinase-1β (RSK-2) and p70S6kinase. FEBS Lett 1997;402:121–23.PubMedCrossRef
32.
Liao X, Thrasher JB, Holzheierlein J, Stanley S, Li B. Glycogen synthase kinase-1β activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 2004;45:2941–49.CrossRef
33.
Mehrhof FB, Muller FU, Bergman MW, Li P, Wang Y, Schmitz W, Dietz R, von Harsdorf R. In cardiomyocyte hypoxia, insulin-like growth factor-1-induced anti-apoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein. Circulation 2001;104:2088–94.PubMedCrossRef
34.
Delghandi MP, Johannessen M, Moens U. The cAMP signaling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells. Cell Signal 2005;17:1343–51.PubMedCrossRef
35.
Tanaka K. Alterations in second messengers during acute cerebral ischemia-adenylate cyclase, cyclic AMP dependent protein kinase and cyclic AMP response element binding protein. Prog Neurobiol 2001;65:173–207.PubMedCrossRef
36.
Thonberg H, Frederiksson JM, Nedergaard H, Cannon B. A novel pathway for adrenergic stimulation of cAMP response-element-binding protein (CREB) phosphorylation-mediation via alpha1-adrenoceptors and protein kinase C activation. Biochem J 2002;364:73–9.PubMed
37.
Li B, Kaetzel MA, Dedman JR. Signaling pathways regulating murine cardiac CREB phosphorylation. Biochem Biophys Res Commun 2006;350:179–84.PubMedCrossRef
38.
Ford DA, Hazen SC, Saffitz JE, Gross RW. The rapid and reversible activation of a calcium-independent plasmalogen-selective phospholipase A2 during myocardial ischaemia. J Clin Invest 1991;88:331–5.PubMedCrossRef
39.
Lawrence KM, Scarabelli TM, Turtle L, Chanalaris A, Townsend PA, Carroll CJ, Hubank M, Stephanou A, Knight RA, Latchman DS. Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium-insensitive phospholipase A2 gene expression. FASEB J 2003;17:2313–15.PubMed
40.
Williams SD, Ford DA. Activation of myocardial cAMP-dependent protein kinase by lysoplasmenylcholine. FEBS Lett 1997;420:33–8.PubMedCrossRef
41.
Pavoine C, Behforouz N, Gauthier C, Le Gouvello S, Roudot-Thoraval F, Martin CR, et al. Beta-2-adrenergic signaling in human heart: shift from the cyclic AMP to the arachidonic acid pathways. Mol Pharmacol 2003;64:1117–25.PubMedCrossRef
42.
Lochner A, Genade S, Hattingh S, Moolman JA, Huisamen B. Comparison between ischaemic and anisomycin-induced preconditioning: role of p38 MAPK. Cardiovasc Drugs Therap 2003;17:217–30.CrossRef
43.
Sandhu R, Diaz RJ, Mao GD, Wilson GJ. Ischemic preconditioning: differences in susceptibility to blockade with single-cycle versus multicycle transient ischemia. Circulation 1997;96:984–95.PubMed
44.
Meller R, Minami M, Cameron A, Impey S, Chen D, Simon J-QP. CREB-mediated Bcl-2 protein expression after ischaemic preconditioning. J Cerebr Blood flow Metab 2005;25:234–46.CrossRef
45.
Lee HT, Chang YC, Wang LY, Wang ST, Huang CC, Ho CJ. cAMP response element-binding protein activation in ligation preconditioning in neonatal brain. Ann Neurol 2004;56:611–23.PubMedCrossRef
46.
Lochner A, Genade S, Tromp E, Podzuweit T, Moolman JA. Ischemic preconditioning and the β-adrenergic signal transduction pathway. Circulation 1999;100:958–66.PubMed
47.
Williams SD, Gottlieb RA. Inhibition of mitochondrial calcium-independent phospholipase A2 (iPLA2) attenuates mitochondrial phospholipid loss and is cardioprotective. Biochem J 2002;362:23–32.PubMedCrossRef
48.
Tokunou T, Shibata R, Kai H, Ichiki T, Movisaki T, Fukuyama K, et al. Apoptosis induced by inhibition of cyclic AMP response element-binding protein in vascular smooth muscle cells. Circulation 2003;108:1246–52.PubMedCrossRef
49.
Rabelo FL, Ramos MG, Brumatti G, Amarante-Mendes GP, Ropert C, Bonjardim CA, et al. Apoptosis induced by butyrate is independent of Jak/STAT signaling in a fibrosarcoma cell line. Biochem Biophys Res Commun 2003;301:968–73.PubMedCrossRef
50.
Jambal P, Masterson S, Nesterova A, Bouchard R, Bergman B, Hutton JC, et al. Cytokine-mediated down-regulation of the transcription factor cAMP-response element-binding protein in pancreatic beta-cells. J Biol Chem 2003;278:23055–65.PubMedCrossRef
51.
Qiao L, Han SI, Fang Y, Park JS, Gupta S, Gilfor D, et al. Bile regulation of C/EBP beta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes. Mol Cell Biol 2003;23:3052–66.PubMedCrossRef
52.
Mayr B, Montiny M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001;2:599–609.PubMedCrossRef
53.
Atsumi G, Murakami M, Kojima K, Hadan O, Jajima M, Kudo L. Distinct roles of two intracellular phospholipase A2s in fatty acid release in the cell death pathway. Proteolytic fragment of type IV A cytosolic phospholipase A2 alpha inhibits stimulus-induced arachidonate release whereas that of type VI Ca2+-independent phospholipase A2 augments spontaneous fatty acid release. J Biol Chem 2000;275:18248–58.PubMedCrossRef
Metadaten
Titel
CREB Activation and Ischaemic Preconditioning
verfasst von
E. Marais
S. Genade
A. Lochner
Publikationsdatum
01.02.2008
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 1/2008
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-007-6078-3

Weitere Artikel der Ausgabe 1/2008

Cardiovascular Drugs and Therapy 1/2008 Zur Ausgabe

Letter to the Editor

Renin Inhibitors in Cardiovascular Surgery

ReviewPaper

Management of Tako-tsubo Syndrome

EditorialNotes

Recombinant Human Epo Treatment: Beneficial in Chronic Kidney Disease, Chronic Heart Failure, or Both?

BriefCommunication

Lipoprotein Associated Phospholipase A2 Inhibition Reduces Generation of Oxidized Fatty Acids

OriginalPaper

Trimetazidine Protective Effect Against Ischemia-Induced Susceptibility to Ventricular Fibrillation in Pigs

OriginalPaper

A Meta-Analysis of Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor in the Treatment of Acute Myocardial Infarction

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise